Recombinant Human ALCAM/CD166 Fc Chimera Avi-tag Protein, CF

When Recombinant Human CD6 Fc Chimera (627-CD) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ALCAM/CD166 Fc Chimera Avi-tag Protein (Catalog # AVI7187) binds with an ED50 of 1.50-12.0 ng/mL.

2 μg/lane of Recombinant Human ALCAM/CD166 Fc Chimera Avi-tag Protein (Catalog # AVI7187) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 100-120 kDa and 200-240 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ALCAM/CD166 Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated (HEK293-expressed)
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD6 Fc Chimera (Catalog # 627-CD) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ALCAM/CD166 Fc Chimera Avi-tag (Catalog # AVI7187) binds with an ED₅₀ of 1.50-12.0 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human ALCAM/CD166 protein
  

  Human ALCAM (Trp28-Ala526) Accession # AAB59499.1	DIEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• N-terminal Sequence: Trp28
• Structure / Form: Disulfide-linked homodimer
  Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 84 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 100-120 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ALCAM/CD166 Fc Chimera Avi-tag Protein, CF

• activated leucocyte cell adhesion molecule
• activated leukocyte cell adhesion moleculeFLJ38514
• ALCAM
• CD166 antigen
• CD166
• MEMDMGC71733

Background

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a surface glycoprotein belonging to the immunoglobulin superfamily (1, 2). ALCAM, along with MCAM and BCAM/Lu, form a small subgroup of adhesion molecules involved in tissue development and maintenance, neurogenesis, and regulation of immune responses (3). Mature human ALCAM consists of an extracellular domain (ECD) containing 2 IgV and 3 IgC domains, a transmembrane domain, and a short cytoplasmic domain (1, 2). Within the ECD, human ALCAM shares 93% amino acid sequence identity with both mouse and rat ALCAM. An isoform of ALCAM with a shorter stalk region in the ECD is known to exist and is associated with higher shedding tendency and decreased cell adhesion (2). Initially found expressed on activated leukocytes, ALCAM expression has been detected in a wide variety of tissues and cells (3, 4). In addition to cell adhesion, other ALCAM functions include leukocyte migration across the blood brain barrier, T-cell activation, and osteogenesis, (2, 5, 6). Overexpression of ALCAM is often associated with poor prognosis in various human tumors, such as bladder cancer, prostate cancer, melanoma, and liver cancer (2, 7). Our Avi-tag Biotinylated Recombinant Human ALCAM features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
2. Ferragut, F. et al. (2021) Cytokine Growth Factor Rev. 61:27.
3. Swart, G.W. (2002) Eur J Cell Biol. 81:313).
4. Zimmerman, A.W. et al. (2006) Blood 107:3212.
5. Masedunskas, A. et al. (2006) FEBS Lett. 580:2637.
6. Cayrol, R. et al. (2008) Nat. Immunol. 9:137.
7. Darvishi, B. et al. (2020) Exp. & Mol. Path 115:104443.